Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 9792363, 6 pages
https://doi.org/10.1155/2017/9792363
Research Article

Assessment of Drug-Drug Interaction in Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia: A Retrospective Study

1Mekelle University, School of Pharmacy, Pharmacoepidemiology and Social Pharmacy Courses and Research Team, Mekelle, Ethiopia
2Department of Pharmacy, Pharmacology and Toxicology Courses and Research Team, Adigrat University, Adigrat, Ethiopia

Correspondence should be addressed to Yared Belete Belay; moc.liamg@betelebderay

Received 13 June 2017; Revised 25 September 2017; Accepted 3 October 2017; Published 8 November 2017

Academic Editor: Yudong Cai

Copyright © 2017 Zeru Gebretsadik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Blower, R. De Wit, S. Goodin, and M. Aapro, “Drug-drug interactions in oncology: Why are they important and can they be minimized?” Critical Review in Oncology/Hematology, vol. 55, no. 2, pp. 117–142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. https://WWW.Drugs.Com/Drug_Interactions.Html.
  3. T. Prueksaritanont, X. Chu, C. Gibson et al., “Drug-drug interaction studies: Regulatory guidance and an industry perspective,” The AAPS Journal, vol. 15, no. 3, pp. 629–645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Buajordet, J. Ebbesen, J. Erikssen, O. Brørs, and T. Hilberg, “Fatal adverse drug events: The paradox of drug treatment,” Journal of Internal Medicine, vol. 250, no. 4, pp. 327–341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. R. M. Goldberg, J. Mabee, L. Chan, and S. Wong, “Drug-drug and drug-disease interactions in the ED: Analysis of a high- risk population,” The American Journal of Emergency Medicine, vol. 14, no. 5, pp. 447–450, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Srikanth, E. Admassie, W. Hailu, T. Melese, and W. Mequanent, “Extent of poly-pharmacy, occurrence and associated factors of drug-drug interaction and potential adverse drug reactions in Gondar Teaching Referral Hospital, North West Ethiopia,” Journal of Advanced Pharmaceutical Technology & Research, vol. 4, no. 4, p. 183, 2013. View at Publisher · View at Google Scholar
  7. B. Demeke, F. Molla, A. Assen, W. Melkam, S. Abrha, and B. Masresha, “Evaluation of drugs utilization pattern using WHO prescribing indicators in Ayder referral hospital, Northern Ethiopia,” International Journal of Pharmaceutical Science and Research, vol. 6, no. 2, pp. 343–347, 2015. View at Google Scholar
  8. A. M. M. Reis and S. H. D. B. Cassiani, “Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil,” Clinics, vol. 66, no. 1, pp. 9–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. ML. Becker, LE. Vissr, T. Van Gelder, and BH. Stricker, “Increasing exposure of drug-drug interactions between 1992 and 2005 in people aged > or =55 yeaars,” Drug Aging, vol. 25, no. 2, pp. 145–151, 1992. View at Google Scholar
  10. J. J. Gagne, V. Maio, and C. Rabinowitz, “Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy,” Journal of Clinical Pharmacy and Therapeutics, vol. 33, no. 2, pp. 141–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Cruciol-Souza and J. C. Thomson, “Prevalence of potential drug-drug interactions and associated factors in Brazilian teaching hospital,” Journal of Pharmaceutical Sciences, vol. 9, pp. 427–433, 2006. View at Google Scholar
  12. Micromedex® HealthCare Series (internet database) Version 2.0, Thomson Healthcare Inc, Greenwood Village, Colorado, 2013, http://www.micromedexsolutions.com.
  13. U. Werneke, J. Earl, C. Seydel, O. Horn, P. Crichton, and D. Fannon, “Potential health risks of complementary alternative medicines in cancer patients,” British Journal of Cancer, vol. 90, no. 2, pp. 408–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. E. E. Roughead, L. M. Kalisch, J. D. Barratt, and A. L. Gilbert, “Prevalence of potentially hazardous drug interactions amongst Australian veterans,” British Journal of Clinical Pharmacology, vol. 70, no. 2, pp. 252–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Vonbach. P., A. Dubied, S. Krahenbuhl et al., “Prevalence of drug-drug interactionat hospital entry and during stay of patients in internal medicine,” International Journal of Internal Medicine, vol. 19, pp. 413–420, 2008. View at Google Scholar
  16. C. D. Miller, R. El-Kholi, J. J. Faragon, and T. P. Lodise, “Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy,” Pharmacotherapy, vol. 27, no. 10, pp. 1379–1386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Barrios, E. Negredo, P. Domingo et al., “Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial,” Antiviral Therapy, vol. 10, no. 7, pp. 825–832, 2005. View at Google Scholar · View at Scopus
  18. A. Assen and S. Abrha, “Assessment of Drug Prescribing Pattern in Dessie Referral Hospital, Dessie,” International Journal for Pharmaceutical Research Scholar, vol. 5, no. 11, pp. 777–781, 2014. View at Google Scholar
  19. A. Case and C. Paxson, “Sex Differences in Morbidity and Mortality,” National Bureau of Economic Research w10653, 2004. View at Publisher · View at Google Scholar
  20. S. Rambhade, A. Chakarborty, A. Shrivastava, U. K. Patil, and A. Rambhade, “A survey on polypharmacy and use of inappropriate medications,” Toxicology International, vol. 19, no. 1, pp. 68–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Maher, J. Hanlon, and E. R. Hajjar, “Clinical consequences of polypharmacy in elderly,” Expert Opinion on Drug Safety, vol. 13, no. 1, pp. 57–65, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Ghei, “How to investigate drug use in health facilities. Selected drug use indicators,” Health Policy, vol. 34, no. 1, p. 73, 1995. View at Publisher · View at Google Scholar
  23. B. Durga and B. Pharm, “Pattern of potential drug-drug interactions in diabetic out-patients in a tertiary care teaching hospital in Nepal,” Medical Journal of Malaysia, vol. 62, no. 4, p. 295, 2007. View at Google Scholar
  24. V. Hasanloei, M. Amin, S. Hamdolah, and H. Aysa, “Drug–Drug Interactions Prevalence in Intensive Care Unit Patients of a University Hospital in Iran,” Bulletin of Environment, Pharmacology and Life Sciences, vol. 3, pp. 87–91, 2014. View at Google Scholar
  25. T. Rajani, S. M. Biradar, K. Sravanthi et al., “Assessment of potential drug-drug interactions in in patients of a medicine ward of a tertiary care hospital,” International Journal of Research in Biosciences, vol. 5, no. 1, pp. 76–82, 2016. View at Google Scholar
  26. H. Kafeel, R. Rukh, H. Qamar et al., “Possibility of drug-drug interaction in prescription dispensed by community and hospital pharmac,” Pharmacology & Pharmacy, vol. 9, 2014. View at Google Scholar
  27. K. Kanagasanthosh, I. Topno, and B. Aravindkumar, “Prevalence of potentially inappropriate medication use and drug utilization pattern in elderly patients: a prospective study from a tertiary care hospital,” International Journal of Research in Medical Sciences, pp. 2062–2072, 2015. View at Publisher · View at Google Scholar
  28. B. Straubhaar, S. Krähenbühl, and R. G. Schlienger, “The prevalence of potential drug-drug interactions in patients with heart failure at hospital discharge,” Drug Safety, vol. 29, no. 1, pp. 79–90, 2006. View at Publisher · View at Google Scholar · View at Scopus